These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23916256)

  • 1. Modulation of NMDA receptor function as a treatment for schizophrenia.
    Cioffi CL
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5034-44. PubMed ID: 23916256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
    Citrome L
    J Clin Psychiatry; 2014; 75 Suppl 1():21-6. PubMed ID: 24581451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
    Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
    Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate signaling in the pathophysiology and therapy of schizophrenia.
    Lin CH; Lane HY; Tsai GE
    Pharmacol Biochem Behav; 2012 Feb; 100(4):665-77. PubMed ID: 21463651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of the D-serine pathway to schizophrenia.
    Labrie V; Wong AH; Roder JC
    Neuropharmacology; 2012 Mar; 62(3):1484-503. PubMed ID: 21295046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.
    Heresco-Levy U; Silipo G; Javitt DC
    Psychopharmacol Bull; 1996; 32(4):731-40. PubMed ID: 8993096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.
    Gilmour G; Dix S; Fellini L; Gastambide F; Plath N; Steckler T; Talpos J; Tricklebank M
    Neuropharmacology; 2012 Mar; 62(3):1401-12. PubMed ID: 21420987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycine modulators in schizophrenia.
    Javitt DC
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
    Labrie V; Roder JC
    Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.